2026 ICD-10-CM Diagnosis Code T38.895SAdverse effect of other hormones and synthetic substitutes, sequela

ICD-10-CM CodesS00–T88T36-T50T38

ICD-10-CM T38.895S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T38.895S is a billable ICD-10-CM diagnosis code for adverse effect of other hormones and synthetic substitutes, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T38.895S
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of other hormones and synthetic substitutes, sequela
Short Description
Adverse effect of hormones and synthetic sub, sequela
Parent Code
Adverse effect of other hormones and synthetic substitutes

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT38Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified
This CodeT38.895SAdverse effect of other hormones and synthetic substitutes, sequela

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T38.895S.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

T38.895S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adverse reaction caused by antidiuretic hormone
  • Adverse reaction to hypothalamic hormone
  • Adverse reaction to posterior pituitary hormones
  • Buserelin adverse reaction
  • Calcium regulating hormone adverse reaction
  • Cyclofenil adverse reaction
  • Desmopressin adverse reaction
  • Gonad regulating hormone adverse reaction
  • Gonadorelin adverse reaction
  • Gonadotrophic hormone adverse reaction
  • Hemostatic adverse reaction
  • Lypressin adverse reaction
  • Nafarelin adverse reaction
  • Protirelin adverse reaction
  • Sex hormones adverse reaction
  • Terlipressin adverse reaction
  • Thyrotropin releasing factor adverse reaction
  • Vasopressor adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Buserelin

    a potent synthetic analog of gonadotropin-releasing hormone with d-serine substitution at residue 6, glycine10 deletion, and other modifications.
  • Chorionic Gonadotropin

    a gonadotropic glycoprotein hormone produced primarily by the placenta. similar to the pituitary luteinizing hormone in structure and function, chorionic gonadotropin is involved in maintaining the corpus luteum during pregnancy. cg consists of two noncovalently linked subunits, alpha and beta. within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (tsh, lh, and fsh), but the beta subunit is unique and confers its biological specificity (chorionic gonadotropin, beta subunit, human).
  • Chorionic Gonadotropin, beta Subunit, Human

    the beta subunit of human chorionic gonadotropin. its structure is similar to the beta subunit of luteinizing hormone, except for the additional 30 amino acids at the carboxy end with the associated carbohydrate residues. hcg-beta is used as a diagnostic marker for early detection of pregnancy, spontaneous abortion (abortion, spontaneous); ectopic pregnancy; hydatidiform mole; choriocarcinoma; or down syndrome.
  • Glycoprotein Hormones, alpha Subunit

    the alpha chain of pituitary glycoprotein hormones (thyrotropin; follicle stimulating hormone; luteinizing hormone) and the placental chorionic gonadotropin. within a species, the alpha subunits of these four hormones are identical; the distinct functional characteristics of these glycoprotein hormones are determined by the unique beta subunits. both subunits, the non-covalently bound heterodimers, are required for full biologic activity.
  • Receptors, LH

    those protein complexes or molecular sites on the surfaces and cytoplasm of gonadal cells that bind luteinizing or chorionic gonadotropic hormones and thereby cause the gonadal cells to synthesize and secrete sex steroids. the hormone-receptor complex is internalized from the plasma membrane and initiates steroid synthesis.
  • Felypressin

    a synthetic analog of lypressin with a phenylalanine substitution at residue 2. felypressin is a vasoconstrictor with reduced antidiuretic activity.
  • Leuprolide

    a potent synthetic long-acting agonist of gonadotropin-releasing hormone that regulates the synthesis and release of pituitary gonadotropins, luteinizing hormone and follicle stimulating hormone.
  • Lypressin

    the porcine antidiuretic hormone (vasopressins). it is a cyclic nonapeptide that differs from arg-vasopressin by one amino acid, containing a lysine at residue 8 instead of an arginine. lys-vasopressin is used to treat diabetes insipidus or to improve vasomotor tone and blood pressure.
  • Sermorelin

    the biologically active fragment of human growth hormone-releasing factor, consisting of ghrh(1-29)-amide. this n-terminal sequence is identical in several mammalian species, such as human, pig, and cattle. it is used to diagnose or treat patients with growth hormone deficiency.
  • Terlipressin

    an inactive peptide prodrug that is slowly converted in the body to lypressin. it is used to control bleeding of esophageal varices and for the treatment of hepatorenal syndrome.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
ADHT38.891T38.892T38.893T38.894T38.895T38.896
Antidiuretic hormoneT38.891T38.892T38.893T38.894T38.895T38.896
BuserelinT38.891T38.892T38.893T38.894T38.895T38.896
Chorionic gonadotropinT38.891T38.892T38.893T38.894T38.895T38.896
DDAVPT38.891T38.892T38.893T38.894T38.895T38.896
Deamino-D-arginine vasopressinT38.891T38.892T38.893T38.894T38.895T38.896
DesmopressinT38.891T38.892T38.893T38.894T38.895T38.896
EnterogastroneT38.891T38.892T38.893T38.894T38.895T38.896
FelypressinT38.891T38.892T38.893T38.894T38.895T38.896
GonadorelinT38.891T38.892T38.893T38.894T38.895T38.896
GonadotropinT38.891T38.892T38.893T38.894T38.895T38.896
Gonadotropin::chorionicT38.891T38.892T38.893T38.894T38.895T38.896
Gonadotropin::pituitaryT38.891T38.892T38.893T38.894T38.895T38.896
Hypophysis, posteriorT38.891T38.892T38.893T38.894T38.895T38.896
LeuprolideT38.891T38.892T38.893T38.894T38.895T38.896
LypressinT38.891T38.892T38.893T38.894T38.895T38.896
Lysine vasopressinT38.891T38.892T38.893T38.894T38.895T38.896
Melanocyte-stimulating hormoneT38.891T38.892T38.893T38.894T38.895T38.896
Pitressin (tannate)T38.891T38.892T38.893T38.894T38.895T38.896
Pituitary extracts (posterior)T38.891T38.892T38.893T38.894T38.895T38.896
Pituitary extracts (posterior)::anteriorT38.891T38.892T38.893T38.894T38.895T38.896
PituitrinT38.891T38.892T38.893T38.894T38.895T38.896
Placental hormoneT38.891T38.892T38.893T38.894T38.895T38.896
Posterior pituitary hormone NECT38.891T38.892T38.893T38.894T38.895T38.896
ProtirelinT38.891T38.892T38.893T38.894T38.895T38.896
SermorelinT38.891T38.892T38.893T38.894T38.895T38.896
SomatorelinT38.891T38.892T38.893T38.894T38.895T38.896
TerlipressinT38.891T38.892T38.893T38.894T38.895T38.896
Thymus extractT38.891T38.892T38.893T38.894T38.895T38.896
VasopressinT38.891T38.892T38.893T38.894T38.895T38.896
Vasopressor drugsT38.891T38.892T38.893T38.894T38.895T38.896

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T38.895S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.5 Lte efct advrs efct drug
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E932.9 Adv eff hormones NEC/NOS
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T38.895SOverview

Is T38.895S (Adverse effect of other hormones and synthetic substitutes) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of other hormones and synthetic substitutes, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T38.895S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of other hormones and synthetic substitutes itself has resolved, not the original event.

What MS-DRG does T38.895S group to?

On inpatient claims, adverse effect of other hormones and synthetic substitutes, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T38.895S be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of other hormones and synthetic substitutes, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is T38.895S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of other hormones and synthetic substitutes, sequela on inpatient claims.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.